Summary:
In individuals with type 2 diabetes, DPP-4 inhibitor (sitagliptin) and bedtime NPH insulin therapy
significantly modulated microRNA expression affecting insulin signaling, inflammation, and cellular homeostasis pathways compared to baseline or standard diabetic treatments without this combination, though it was associated with potential pleiotropic effects beyond glycemic control.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes mellitus undergoing pharmacological treatment. |
| Intervention | Combined therapy using DPP-4 inhibitor sitagliptin and bedtime neutral protamine Hagedorn (NPH) insulin. |
| Comparison | Standard diabetes treatment regimens without the addition of DPP-4 inhibitor and bedtime NPH insulin. |
| Outcome | Significant modulation of microRNAs involved in insulin signaling, inflammation, and cellular homeostasis pathways, indicating pleiotropic benefits beyond glycemic control. |
Source: Aritania Sousa Santos, et al. “MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes.” Read article here.
